New oral treatment for hyperkalaemia

Veltassa (patiromer) is a powder for oral suspension licensed for the treatment of hyperkalaemia in adults.

Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion. The drug increases faecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen resulting in reduced serum potassium.

Each Veltassa sachet contains 8.4g or 16.8g patiromer (as sorbitex calcium) to be mixed with approximately 80ml water, apple or cranberry juice. The mixture should be taken within one hour of initial suspension.

The product information for Veltassa states that there is limited experience in patients with serum potassium concentrations greater than 6.5mmol/l and in those with end-stage renal disease (eGFR <15ml/min/1.73m2) or on dialysis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...